Obagi Medical Products, Inc. (OMPI) Tops Q1 EPS by 3c; Guides Lower
Tweet
Share
E-mailGet Alerts OMPI Hot Sheet
Join SI Premium – FREE
Obagi Medical Products, Inc. (NASDAQ: OMPI) reported Q1 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $28.4 million versus the consensus estimate of $27.11 million.
Obagi Medical Products, Inc. sees FY2011 EPS of $0.78-$0.78, versus the consensus of $0.89. Obagi Medical Products, Inc. sees FY2011 revenue of $114-$116 million, versus the consensus of $120.6 million.
Obagi Medical Products, Inc. sees Q2 2011 EPS of $0.15-$0.17, versus the consensus of $0.23. Obagi Medical Products, Inc. sees Q2 2011 revenue of $26.5-$28 million, versus the consensus of $30.67 million.
Obagi Medical Products, Inc. sees FY2011 EPS of $0.78-$0.78, versus the consensus of $0.89. Obagi Medical Products, Inc. sees FY2011 revenue of $114-$116 million, versus the consensus of $120.6 million.
Obagi Medical Products, Inc. sees Q2 2011 EPS of $0.15-$0.17, versus the consensus of $0.23. Obagi Medical Products, Inc. sees Q2 2011 revenue of $26.5-$28 million, versus the consensus of $30.67 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
